Business ❯ Finance

Investment Deals

Tech Industry Pharmaceutical Investments Valuation Corporate Partnerships Early-Stage Deals Series A Funding Stock Acquisitions Public Investment Fund Cloud Services Upfront Payments Technology Investments Sports Investments Venture Capital Corporate Valuation Ralf Dümmel Luxury Fashion Loan Agreements Cash Flow Management Milestone Payments Cash and Stock Transactions OpenAI Funding Microsoft Funding Amounts Securities and Exchange Commission Filings Partnerships Luxury Real Estate Market Trends Long-term Agreements Shareholder Agreements Acquisition Costs Majority Stake Out-licensing Streaming Agreements Biopharmaceuticals

Spero Licenses Innovent’s Anti‑CD40L Antibody Outside Greater China in Up to $1.1 Billion Deal

The agreement gives Innovent immediate cash plus milestone and royalty upside while positioning Spero to build an immunology program and advance mid‑stage trials next year.

Pfizer and Innovent Strike Up to $10.5 Billion Oncology Collaboration

AstraZeneca Strikes $1.2 Billion CSPC Pact for Once‑Monthly Obesity and Diabetes Programs

Biogen Licenses Vanqua’s Preclinical C5aR1 Drug in Deal Worth Up to $1.06 Billion

Musk’s Bid to Include xAI in UAE AI Hub Blocked as Deal Moves Forward